Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC

Chengxiang Yi; Yayi He; Haoran Xia; Helin Zhang; Peng Zhang

doi:10.2147/OTT.S218321

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC

Onco Targets Ther. 2019 Sep 6:12:7329-7336. doi: 10.2147/OTT.S218321. eCollection 2019.

Authors

Chengxiang Yi^#^{1

2}, Yayi He^#³, Haoran Xia^#¹, Helin Zhang⁴, Peng Zhang¹

Affiliations

¹ Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, People's Republic of China.
² Tongji University School of Medicine, Tongji University, Shanghai 200433, People's Republic of China.
³ Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People's Republic of China.
⁴ Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang City, People's Republic of China.

^# Contributed equally.

Abstract

Postoperative patients have risk recurring, even for completed resected early stage non-small-cell lung cancer (NSCLC). To control the recurrence rate, neoadjuvant and adjuvant therapies have been applied widely in clinical practice; however, neoadjuvant and adjuvant immunotherapy clinical trials on NSCLC are still being explored. In this review, we summarized the research progress and outline the issues need to be solved on adjuvant and neoadjuvant immunotherapies in NSCLC.

Keywords: adjuvant immunotherapies; biomarker; immune checkpoint inhibitor; liquid biopsy; neoadjuvant immunotherapies; non-small-cell lung cancer.